Immunosuppression in aplastic anemia — postponing the inevitable? Journal Article

  


Authors: Moore, M. A. S.; Castro-Malaspina, H.
Article Title: Immunosuppression in aplastic anemia — postponing the inevitable?
Abstract: Mathé et al. reported in 1970 that when some patients with aplastic anemia received an allogeneic marrow transplant together with a conditioning immunosuppressive regimen of antilymphocyte globulin, they recovered autologous hematopoietic function.1 Subsequent trials of antilymphocyte globulin or antithymocyte globulin, alone or with steroids, resulted in hematologic improvement in 40 to 80 percent of patients with severe aplastic anemia. This effect was matched by improvement in one-year survival, from less than 25 percent with androgens alone to 40 to 75 percent with antilymphocyte globulin2 3 4 5 6 — a rate comparable to the 60 to 80 percent survival with transplantation of bone marrow. © 1991, Massachusetts Medical Society. All rights reserved.
Keywords: drug efficacy; editorial; methylprednisolone; immunosuppressive treatment; cyclosporin; thymocyte antibody; aplastic anemia; lymphocyte antibody; human; priority journal
Journal Title: New England Journal of Medicine
Volume: 324
Issue: 19
ISSN: 0028-4793
Publisher: Massachusetts Medical Society  
Date Published: 1991-05-09
Start Page: 1358
End Page: 1360
Language: English
DOI: 10.1056/nejm199105093241909
PUBMED: 2017233
PROVIDER: scopus
DOI/URL:

https://www.scopus.com/inward/record.uri?eid=2-s2.0-0025727282&doi=10.1056%2fNEJM199105093241909&partnerID=40&md5=113f43643d9ae5a5ead4f93f54af631a
Notes: Editorial -- Source: Scopus
Altmetric
What is Altmetric?
Citation Impact
What is Dimensions Citation Badge?
BMJ Impact Analytics
MSK Authors
  1. Hugo Castro-Malaspina
    333 Castro-Malaspina
  2. Malcolm A S Moore
    549 Moore
Related MSK Work